The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known by brand names Ozempic and Wegovy, has the ability to counter metabolic dysfunction-associated steatohepatitis, or MASH, liver disease and some of its risk factors.

Researchers from the Karolinska Institutet in Sweden have found a potential new treatment for non-alcoholic fatty liver disease (NAFLD), a condition that affects many people with type 2 diabetes and obesity.

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.